From 23 June 2025, Tirzepatide (Mounjaro®) will be available on the NHS for patients with a BMI over 40 and at least four qualifying conditions (hypertension, sleep apnoea, type 2 diabetes, cardiovascular disease, or high cholesterol). Eligible patients will be contacted directly for assessment. Please do not contact the surgery.